39 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
chain. While Takeda has endeavored to be carbon neutral since 2020 (reflecting FY2019 greenhouse gas emissions), beginning in FY2024 we will fully … dedicate our resources to decarbonizing our operations and value chain to support our net-zero ambition, and will no longer have carbon neutrality
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:24am
maintained carbon neutrality through FY2022, in FY2024 we have transitioned away from carbon neutrality as a climate goal and are focusing resources … on initiatives that advance our net-zero roadmap while continuing to invest in nature-based carbon removal projects in projects beyond our value chain. We
6-K
TAK
Takeda Pharmaceutical Co
9 May 24
Current report (foreign)
6:01am
and working to eliminate greenhouse gas (GHG) emissions from our entire value chain. While Takeda has maintained carbon neutrality through FY2022, in FY2024 we … have transitioned away from carbon neutrality as a climate goal and are focusing resources on initiatives that advance our net-zero roadmap while
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas
6-K
EX-99.1
i1lf3ase
14 Dec 23
Current report (foreign)
6:01am
6-K
EX-99.1
z47eif1v6apeb 1j
30 Nov 23
Current report (foreign)
6:01am
6-K
EX-99.1
sabkcq2v
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
bvsqjirr
26 Oct 23
Current report (foreign)
6:20am
6-K
EX-99.1
o9sz2k8l0
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
d2rcavhlet 22xw4
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
no5 tomog
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
nsaw1i mu2xk
11 May 23
Current report (foreign)
6:07am
6-K
738a d5gw8whqfb
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
mlrvl4flrcu6g3
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
fdobh4tw6
27 Oct 22
Current report (foreign)
6:01am
6-K
EX-99.1
28y14
4 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
9n1n j7qo6
28 Jul 22
Current report (foreign)
6:09am
6-K
gv0u7xrmn4ax2
11 Jul 22
Current report (foreign)
6:05am